A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
1230 details |
| Primary information | |
|---|---|
| ThPP ID | Th1031 |
| Therapeutic Peptide/Protein Name | Interferon Alfa-2a, Recombinant |
| Sequence | CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKA view full sequnce in fasta |
| Functional Classification | Ib |
| Molecular Weight | 19241.1 |
| Chemical Formula | C860H1353N227O255S9 |
| Isoelectric Point | 5.99 |
| Hydrophobicity | -0.336 |
| Melting Point (℃) | N.A. |
| Half Life | Half-life for IV infusion is 3.7 hours to 8.5 hours (mean 5.1 hours). |
| Description | Its a type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences. |
| Indication/Disease | For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection. |
| Pharmacodynamics | Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a bbetter target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2-5 oligoadenylate synthetase (2-5 A synthetase) and protein kinase R. |
| Mechanism of Action | It binds directly to the type II interferon gamma receptor IFNGR1, leading to a complex of IFNGR1 and IFNGR2. This activates JAK1 and JAK2 kinases which form a STAT1 docking site. This leads to STAT1 phosphorylation, nuclear translocation and initiation of gene transcription of multiple immune-related genes. |
| Toxicity | Interferon alfa-2 may cause serious adverse effects such as anemia; autoimmune diseases, including vasculitis, arthritis, hemolytic anemia, and erythematosus syndrome; cardiotoxicity; hepatotoxicity; hyperthyroidism or hypothyroidism; transient ischemic a |
| Metabolism | N.A. |
| Absorption | Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously. |
| Volume of Distribution | 0.223 to 0.748 L/kg [healthy people] |
| Clearance | 2.14 - 3.62 mL/min/kg [healthy] |
| Categories | N.A. |
| Patents Number | N.A. |
| Date of Issue | N.A. |
| Date of Expiry | N.A. |
| Drug Interaction | Aminophylline interferon increases the effect and toxicity of theophylline |
| Target | N.A. |
| Information of corresponding available drug in the market | |
| Brand Name | N.A. |
| Company | N.A. |
| Brand Discription | N.A. |
| Prescribed for | N.A. |
| Chemical Name | N.A. |
| Formulation | N.A. |
| Physcial Appearnce | N.A. |
| Route of Administration | N.A. |
| Recommended Dosage | N.A. |
| Contraindication | Autoimmune hepatitis or hepatic decompensation (Child-Pugh class B and C) before or during treatment. |
| Side Effects | N.A. |
| Useful Link | http://www.rxlist.com/roferon-a-drug.htm |
| PubMed ID | 3598612 |
| 3-D Structure | Th1031 (View) or (Download) |